Skip to content
Screener

Interest Income at other companies

Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$8.49M+29.7%
Assembly Biosciences logo
Assembly BiosciencesASMB
$2.29M+104%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$842K-19.2%
Janux Therapeutics logo
Janux TherapeuticsJANX
$9.72M-13.7%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$3.16M+168%

Other financials

Income statement

See full
Revenue$238.9M+19,583%
Gross profit$238.9M+19,763%
Operating income$73.5M+162%
Net income$80.1M+172%
EPS (diluted)$0.47+159%

Balance sheet

See full
Cash & equivalents$287.6M-6.1%
Total debt$93.3M-8.8%
Total equity$982.5M+3.7%
Total assets$1.2B+1.9%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$32.0K-98.7%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.5B+153%
Enterprise value$1.31B+235%
P/S-26.3×

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-92.4%-45.5pp
Net margin-83%-40.9pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-26.1%-7.9pp
Debt / equity0.1×0.0×
Current ratio-1.0×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053549
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Income (loss) from operations73,467(118,417)(58,823)(257,964)
Other income:
Change in fair value of equity investments(1,723)(3,382)(1,893)3,000
Interest income8,96610,78516,15523,073
Other (expense) income, net(451)226(705)154
Total other income6,7927,62913,55726,227
Income (loss) before provision for income taxes80,259(110,788)(45,266)(231,737)
Provision for income taxes(179)(170)(349)(186)

Item 1. Financial Statements (unaudited)

FAQ

What is Vir Biotechnology, Inc.'s interest income?
Vir Biotechnology, Inc. (VIR) reported interest income of $8.97M in Q2 2026.
How has Vir Biotechnology, Inc.'s interest income changed year-over-year?
Vir Biotechnology, Inc.'s interest income decreased by 16.9% year-over-year, from $10.79M to $8.97M.
What is the long-term trend for Vir Biotechnology, Inc.'s interest income?
Over 2 years (2022 to 2025), Vir Biotechnology, Inc.'s interest income has grown at a 19.7% compound annual growth rate (CAGR), from $28.09M to $40.24M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about Vir Biotechnology, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude